» Articles » PMID: 36313902

Detection of Complement C1q B Chain Overexpression and Its Latent Molecular Mechanisms in Cervical Cancer Tissues Using Multiple Methods

Overview
Journal Int J Genomics
Publisher Wiley
Date 2022 Oct 31
PMID 36313902
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The aim of this study is to demonstrate the expression and clinicopathological significance of complement C1q B chain () in cervical cancer.

Methods: In total, 120 cervical cancer tissues, as well as 20 samples each of high-grade squamous intraepithelial lesions (HSILs), low-grade squamous intraepithelial lesions (LSILs), and benign cervical tissue, were collected to evaluate the expression of protein via immunohistochemical staining. We conducted an integrated analysis of mRNA expression in cervical cancer using public microarrays and RNA-seq data sets by calculating standard mean differences (SMDs). Simultaneously, we explored the relations of with clinicopathological parameters and the expression of P16, Ki-67, and P53.

Results: The expression of protein was higher in cervical cancer samples than that in benign cervical tissue, LSIL, and HSIL samples ( < 0.05). A combined SMD of 0.65 (95% CI: [0.52, 0.79], < 0.001) revealed upregulation of mRNA in cervical cancer. expression may also be related to the depth of infiltration, lymphovascular invasion, and perineural invasion in cervical cancer ( < 0.05). We also found that protein expression was positively correlated with P16 and Ki-67 expression in cervical cancer ( < 0.05). The gene set enrichment analysis showed that may participate in apoptosis and autophagy. A relationship was predicted between expression and drug sensitivity to cisplatin, paclitaxel, and docetaxel.

Conclusion: We confirmed the overexpression of in cervical cancer at both mRNA and protein levels for the first time. may serve as an oncogene in the tumorigenesis of cervical cancer, but this possibility requires further study.

Citing Articles

A Robust Proteomics-Based Method for Identifying Preferred Protein Targets of Synthetic Glycosaminoglycan Mimetics.

Afosah D, Ongolu R, Fayyad R, Hawkridge A, Desai U bioRxiv. 2025; .

PMID: 39896571 PMC: 11785238. DOI: 10.1101/2025.01.23.634492.


Identification of key genes associated with endometriosis and endometrial cancer by bioinformatics analysis.

Ma R, Zheng Y, Wang J, Xu H, Zhang R, Xie Z Front Oncol. 2024; 14:1387860.

PMID: 39650066 PMC: 11620973. DOI: 10.3389/fonc.2024.1387860.


Integrated analysis of bulk and single-cell RNA-seq data reveals cell differentiation-related subtypes and a scoring system in bladder cancer.

Li S, Zheng F, Wang Z, Xiong S, Zeng J, Xu S J Cell Mol Med. 2024; 28(19):e70111.

PMID: 39400959 PMC: 11481023. DOI: 10.1111/jcmm.70111.

References
1.
Han C, Zhao F, Wan C, He Y, Chen Y . Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions. Oncol Lett. 2020; 20(1):884-892. PMC: 7286137. DOI: 10.3892/ol.2020.11634. View

2.
Chen L, Liu J, Lu Y, He X, Zhang C, Zhou H . Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential Prognostic Factor and an Index of Tumor Microenvironment Remodeling in Osteosarcoma. Front Oncol. 2021; 11:642144. PMC: 8166322. DOI: 10.3389/fonc.2021.642144. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Mangogna A, Belmonte B, Agostinis C, Zacchi P, Iacopino D, Martorana A . Prognostic Implications of the Complement Protein C1q in Gliomas. Front Immunol. 2019; 10:2366. PMC: 6795702. DOI: 10.3389/fimmu.2019.02366. View

5.
Wei X, He J, Gao B, Han L, Mao Y, Zhao H . Hellebrigenin anti-pancreatic cancer effects based on apoptosis and autophage. PeerJ. 2020; 8:e9011. PMC: 7213012. DOI: 10.7717/peerj.9011. View